AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie.

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 2a multicenter study ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 1b clinical study ...

Trump calls for API stockpile, OCOchem to scale up chemicals from carbon dioxide, Covestro to buy isocyanates plants, and ...

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today the newest addition to the SkinMedica® HA5® Hydra Collagen portfolio. Featuring the brand's proprietary HA5® Hydra Collagen Complex ...

US broadcaster CNN has visited Westport to investigate the potential impact of Donald Trump’s tariffs on the Mayo town. The ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

In a significant move, CSL has announced plans to cut nearly 3,000 jobs and spin off its vaccines unit as part of a major corporate restructuring. This decision comes as the company navigates the ...

Study finds sensory cells that detect tissue damage, irritants also rein in harmful immune responses to protect the lungs ...

Glenmark Pharma stock has tanked over 5 per cent after the company reported lower-than-expected performance in the June 2025 ...

The global monoclonal antibody therapeutics market is set to witness a growth rate of ~12% in the next 5 years. Rising ...